PPSV23 Pneumococcal Vaccine in Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
Streptococcus pneumoniae is the most common causes of community-acquired pneumonia and
exacerbations in chronic obstructive pulmonary disease (COPD) patients, which are associated
with morbidity, mortality, and higher health-care cost. In addition, recently high daily dose
of inhaled corticosteroid (ICS) therapy became more evident to be beneficial in
moderate-to-severe COPD patients, but excess risk of pneumonia shown in database analysis was
worried about by primary physicians. The use of pneumococcal polysaccharide vaccination
(PPSV23) has protective efficacy to eliminate infection of Streptococcus pneumoniae from
previous studies. If the use of PPSV23 can reduce the incidence of pneumonia or exacerbations
in COPD patients using high daily dose of ICS, the benefit of ICS can be preserved and risk
of pneumonia can be reduced. However, there is only limited data supporting this hypothesis.
In this study, the investigators will conduct a double-blinded, randomized controlled trial
to evaluate the clinical efficacy of PPSV23 in severe COPD patients using high daily dose of
ICS.